Adding fuel to the fire: Immunogenic intensification

The durable long term clinical benefits seen for certain patients treated with immunotherapy agents has suggested there is significant therapeutic potential to be derived from these agents, as shown by the increasing prominence of this treatment strategy in upcoming clinical trials. There has been a...

Full description

Saved in:
Bibliographic Details
Published in:Human vaccines & immunotherapeutics 2014-11, Vol.10 (11), p.3306-3312
Main Authors: O'Sullivan Coyne, Geraldine, Gulley, James L
Format: Article
Language:English
Subjects:
activated T cell
Antibodies, Monoclonal - immunology
Antibodies, Monoclonal - therapeutic use
Antigens, Neoplasm - immunology
cancer
Cancer Vaccines - immunology
Cancer Vaccines - therapeutic use
checkpoint inhibitor
Humans
immunogenic intensification
Immunotherapy - methods
Neoplasms - immunology
Neoplasms - therapy
PD-L1
Review
T-Lymphocytes, Cytotoxic - immunology
Tumor Microenvironment - immunology
vaccine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The durable long term clinical benefits seen for certain patients treated with immunotherapy agents has suggested there is significant therapeutic potential to be derived from these agents, as shown by the increasing prominence of this treatment strategy in upcoming clinical trials. There has been a renewed interest and focus on the drivers of tumoral antigen recognition, and the pathways by which various cells of the immune system can stimulate, propagate and execute an effective anti-tumor response. Various challenges lie ahead in the further development of these treatments, including induction of an endogenous anti-tumor response, tumor microenvironment modulation, and T-cell response amplification. Novel treatment combinations may prove of significant added benefit by immunogenic intensification.
ISSN:2164-5515
2164-554X
DOI:10.4161/21645515.2014.973318